Adoptive cellular immunotherapy for the treatment of patients with breast cancer: A meta-analysis
Adoptive cellular immunotherapy for the treatment of patients with breast cancer: A meta-analysis
复制标题
过继细胞免疫疗法治疗乳腺癌患者：荟萃分析
DOI：
10.1016/j.jcyt.2014.02.011
复制
发表时间：
2014-07-01
期刊：
影响因子：
4.5
通讯作者：
Li, Jun-Li
中科院分区：
文献类型：
--
作者：
Wang, Zheng-Xu;Gao, Jun-Xia;Li, Jun-Li
背景为了评价树突状细胞（DC）单独、烟碱诱导的杀伤（CIK）细胞单独以及DC和CIK细胞联合治疗乳腺癌的疗效，我们对相关已发表的临床研究进行了系统回顾，统称为DC-CIK细胞治疗。方法. 633例乳腺癌患者被分配到队列，并进行荟萃分析。结果用DC-CIK细胞治疗乳腺癌与显著改善的1年生存率相关（P = 0.0001）。DC-CIK细胞治疗组患者的Kamofsky体力状态评分较非DC-CIK细胞治疗组明显改善（P < 0.0001）。恶性肿瘤患者外周血T细胞（CD 3+、CD 4+、CD 4 + CD 8+）、CD 16+单核细胞、CD 3 + CD 56+自然杀伤T细胞的百分比显著升高（P
Background. To evaluate the therapeutic efficacy of dendritic cells (DC) alone, cytokine-induced killer (CIK) cells alone and the combination of DC and CIK cells in the treatment of breast cancer, we performed a systemic review of the relevant published clinical studies, collectively referred to as DC-CIK cell therapy. Methods. Six hundred thirty-three patients with breast cancer were assigned to cohorts, and a meta-analysis was conducted. Results. The treatment of breast cancer with DC-CIK cells was associated with a significantly improved 1-year survival (P = 0.0001). The Kamofsky performance status scale of the patients treated with DC-CIK cells was significantly improved compared with that of the non-DC-CIK group (P < 0.0001). The percentage of T cells (CD3(+), CD4(+) and CD4(+)CD8(+)), CD16(+) monocytes, and CD3(+)CD56(+) natural killer T cells in the peripheral blood of cancer patients was significantly increased (P